EA201391131A1 - Сочетания с мацитентаном для лечения полиморфной глиобластомы - Google Patents
Сочетания с мацитентаном для лечения полиморфной глиобластомыInfo
- Publication number
- EA201391131A1 EA201391131A1 EA201391131A EA201391131A EA201391131A1 EA 201391131 A1 EA201391131 A1 EA 201391131A1 EA 201391131 A EA201391131 A EA 201391131A EA 201391131 A EA201391131 A EA 201391131A EA 201391131 A1 EA201391131 A1 EA 201391131A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment
- mattientan
- gliooblastomes
- polymorphic
- combinations
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 231100000433 cytotoxic Toxicity 0.000 abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 abstract 2
- 230000001472 cytotoxic effect Effects 0.000 abstract 2
- 238000001959 radiotherapy Methods 0.000 abstract 2
- 206010018338 Glioma Diseases 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 208000029824 high grade glioma Diseases 0.000 abstract 1
- 201000011614 malignant glioma Diseases 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 229960004964 temozolomide Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2011050494 | 2011-02-04 | ||
| PCT/IB2012/050513 WO2012104822A1 (en) | 2011-02-04 | 2012-02-03 | Combinations comprising macitentan for the treatment of glioblastoma multiforme |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201391131A1 true EA201391131A1 (ru) | 2013-12-30 |
Family
ID=45787254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201391131A EA201391131A1 (ru) | 2011-02-04 | 2012-02-03 | Сочетания с мацитентаном для лечения полиморфной глиобластомы |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20130310407A1 (enExample) |
| EP (2) | EP2670405B1 (enExample) |
| JP (2) | JP5642892B2 (enExample) |
| KR (1) | KR101563069B1 (enExample) |
| CN (1) | CN103327975A (enExample) |
| AR (1) | AR085132A1 (enExample) |
| AU (1) | AU2012213036A1 (enExample) |
| BR (1) | BR112013019680A2 (enExample) |
| CA (1) | CA2823994A1 (enExample) |
| CL (1) | CL2013002193A1 (enExample) |
| CO (1) | CO6761366A2 (enExample) |
| EA (1) | EA201391131A1 (enExample) |
| IL (1) | IL227747A0 (enExample) |
| MA (1) | MA34952B1 (enExample) |
| MX (1) | MX2013008798A (enExample) |
| PH (1) | PH12013501461A1 (enExample) |
| SG (1) | SG192600A1 (enExample) |
| TN (1) | TN2013000333A1 (enExample) |
| TW (1) | TW201309298A (enExample) |
| WO (1) | WO2012104822A1 (enExample) |
| ZA (1) | ZA201306613B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007031933A2 (en) | 2005-09-12 | 2007-03-22 | Actelion Pharmaceuticals Ltd | Stable pharmaceutical composition comprising a pyrimidine-sulfamide |
| ES2543280T3 (es) | 2009-08-10 | 2015-08-17 | Board Of Regents, The University Of Texas System | Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico |
| CN103397308A (zh) * | 2013-08-01 | 2013-11-20 | 光垒光电科技（上海）有限公司 | 用于mocvd设备的喷淋头 |
| TWI559928B (en) * | 2014-08-20 | 2016-12-01 | Academia Sinica | Methods for enhancing permeability to blood-brain barrier and uses thereof |
| KR101701619B1 (ko) | 2015-06-26 | 2017-02-01 | 건양대학교산학협력단 | 뇌교종 세포 치료를 위한 테모졸로마이드와 비타민 d가 포함된 조성물 |
| KR102574253B1 (ko) | 2020-12-15 | 2023-09-07 | 주식회사 시선테라퓨틱스 | 펩티드 핵산 복합체를 유효성분으로 함유하는 교모세포종 예방 또는 치료용 조성물 |
| CN115317604B (zh) * | 2022-08-11 | 2023-09-22 | 南京脑科医院 | 一种靶向胶质瘤的共载放疗增敏阳离子纳米制剂及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1345920E (pt) * | 2000-12-18 | 2006-08-31 | Actelion Pharmaceuticals Ltd | Novas sulfonamidas e sua utilizacao como antagonistas dos receptores de endotelina |
| WO2007031933A2 (en) | 2005-09-12 | 2007-03-22 | Actelion Pharmaceuticals Ltd | Stable pharmaceutical composition comprising a pyrimidine-sulfamide |
| WO2008111092A1 (en) * | 2007-03-09 | 2008-09-18 | Fresenius Kabi Oncology Limited | Crystalline temozolomide monohydrate and process for preparation thereof |
| DK2254570T3 (da) | 2008-02-20 | 2014-02-03 | Actelion Pharmaceuticals Ltd | Kombination omfattende paclitaxel til behandling af ovariecancer |
| ES2543280T3 (es) * | 2009-08-10 | 2015-08-17 | Board Of Regents, The University Of Texas System | Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico |
-
2012
- 2012-02-03 EA EA201391131A patent/EA201391131A1/ru unknown
- 2012-02-03 CA CA2823994A patent/CA2823994A1/en not_active Abandoned
- 2012-02-03 CN CN2012800059659A patent/CN103327975A/zh active Pending
- 2012-02-03 PH PH1/2013/501461A patent/PH12013501461A1/en unknown
- 2012-02-03 MX MX2013008798A patent/MX2013008798A/es active IP Right Grant
- 2012-02-03 WO PCT/IB2012/050513 patent/WO2012104822A1/en not_active Ceased
- 2012-02-03 AU AU2012213036A patent/AU2012213036A1/en not_active Abandoned
- 2012-02-03 KR KR1020137023170A patent/KR101563069B1/ko not_active Expired - Fee Related
- 2012-02-03 MA MA36217A patent/MA34952B1/fr unknown
- 2012-02-03 US US13/983,383 patent/US20130310407A1/en not_active Abandoned
- 2012-02-03 EP EP12706925.0A patent/EP2670405B1/en not_active Not-in-force
- 2012-02-03 JP JP2013552318A patent/JP5642892B2/ja not_active Expired - Fee Related
- 2012-02-03 EP EP15178064.0A patent/EP2965757A1/en not_active Withdrawn
- 2012-02-03 BR BR112013019680A patent/BR112013019680A2/pt not_active IP Right Cessation
- 2012-02-03 TW TW101103560A patent/TW201309298A/zh unknown
- 2012-02-03 AR ARP120100357A patent/AR085132A1/es unknown
- 2012-02-03 SG SG2013058979A patent/SG192600A1/en unknown
-
2013
- 2013-07-10 CO CO13163973A patent/CO6761366A2/es not_active Application Discontinuation
- 2013-07-31 CL CL2013002193A patent/CL2013002193A1/es unknown
- 2013-08-01 TN TNP2013000333A patent/TN2013000333A1/fr unknown
- 2013-08-01 IL IL227747A patent/IL227747A0/en unknown
- 2013-09-03 ZA ZA2013/06613A patent/ZA201306613B/en unknown
-
2014
- 2014-10-28 JP JP2014219218A patent/JP2015057409A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2013002193A1 (es) | 2014-05-09 |
| MA34952B1 (fr) | 2014-03-01 |
| EP2965757A1 (en) | 2016-01-13 |
| TW201309298A (zh) | 2013-03-01 |
| WO2012104822A1 (en) | 2012-08-09 |
| AU2012213036A1 (en) | 2013-09-19 |
| CN103327975A (zh) | 2013-09-25 |
| EP2670405B1 (en) | 2015-09-02 |
| JP2015057409A (ja) | 2015-03-26 |
| JP2014504636A (ja) | 2014-02-24 |
| BR112013019680A2 (pt) | 2016-10-11 |
| MX2013008798A (es) | 2013-10-17 |
| KR101563069B1 (ko) | 2015-10-23 |
| CA2823994A1 (en) | 2012-08-09 |
| JP5642892B2 (ja) | 2014-12-17 |
| KR20130118981A (ko) | 2013-10-30 |
| IL227747A0 (en) | 2013-09-30 |
| ZA201306613B (en) | 2015-04-29 |
| US20130310407A1 (en) | 2013-11-21 |
| EP2670405A1 (en) | 2013-12-11 |
| CO6761366A2 (es) | 2013-09-30 |
| AR085132A1 (es) | 2013-09-11 |
| PH12013501461A1 (en) | 2019-03-22 |
| SG192600A1 (en) | 2013-09-30 |
| TN2013000333A1 (en) | 2015-01-20 |
| NZ615005A (en) | 2015-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3725810T1 (sl) | Kombinacijska terapija, ki vključuje protitelesa proti klavdinu 18.2 za zdravljenje raka | |
| EA201171367A1 (ru) | Винилиндазолильные соединения | |
| EA201400178A1 (ru) | Лечение рака молочной железы | |
| IL239007B (en) | Eribulin for use in the treatment of breast cancer | |
| CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| CL2012000772A1 (es) | Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata. | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| MX2016002974A (es) | Eteres de arilo y sus usos. | |
| MX2013006392A (es) | Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1. | |
| EA201491447A1 (ru) | Ендиины, их конъюгаты и способы их получения и применения | |
| GT201500071A (es) | Antiandrògenos para el tratamiento del cancer de prostata residente a la castracion no metastàsico3 | |
| CL2013001009A1 (es) | Compuestos heterociclicos fusionados; composicion farmaceutica que los comprende, y uso en el tratamiento de un trastorno proliferativo tal como cancer. | |
| EA201300610A1 (ru) | Хиназолинкарбоксамидазетидины | |
| EA201391131A1 (ru) | Сочетания с мацитентаном для лечения полиморфной глиобластомы | |
| CL2015001202A1 (es) | Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer. | |
| CL2015003595A1 (es) | Inhibidores/antiandrógenos novedosos de cyp17 | |
| UA114417C2 (uk) | Інгібітори iap | |
| EA201291329A1 (ru) | Гетероциклические соединения, их получение и их терапевтическое применение | |
| HUE045445T2 (hu) | Kombinált terápia petefészekrák kezelésére | |
| CL2012003322A1 (es) | Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer. | |
| MX2020009966A (es) | Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina. | |
| CR20150148A (es) | Azaindolinas | |
| FI20126281L (fi) | Temotsolomidin polymeeripartikkelipohjainen annosmuoto pahanlaatuisten kasvainten hoitoon | |
| UA117809C2 (uk) | Похідні бендамустину, споріднені сполуки та їхнє медичне застосування для лікування раку | |
| MX2014012535A (es) | Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos. |